The information on this page is current as of Mar 22, 2024.
For the most up-to-date version of CFR Title 21, go to the Electronic Code of Federal Regulations (eCFR).
TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER D - DRUGS FOR HUMAN USE
Subpart A - General Provisions
§ 314.1 - Scope of this part.
§ 314.2 - Purpose.
§ 314.3 - Definitions.
Subpart B - Applications
§ 314.50 - Content and format of an NDA.
§ 314.52 - Notice of certification of invalidity, unenforceability, or noninfringement of a patent.
§ 314.53 - Submission of patent information.
§ 314.54 - Procedure for submission of a 505(b)(2) application requiring investigations for approval of a new indication for, or other change from, a listed drug.
§ 314.55 - Pediatric use information.
§ 314.60 - Amendments to an unapproved NDA, supplement, or resubmission.
§ 314.65 - Withdrawal by the applicant of an unapproved application.
§ 314.70 - Supplements and other changes to an approved NDA.
§ 314.71 - Procedures for submission of a supplement to an approved application.
§ 314.72 - Change in ownership of an application.
§ 314.80 - Postmarketing reporting of adverse drug experiences.
§ 314.81 - Other postmarketing reports.
§ 314.90 - Waivers.
Subpart C - Abbreviated Applications
§ 314.92 - Drug products for which abbreviated applications may be submitted.
§ 314.93 - Petition to request a change from a listed drug.
§ 314.94 - Content and format of an ANDA.
§ 314.95 - Notice of certification of invalidity, unenforceability, or noninfringement of a patent.
§ 314.96 - Amendments to an unapproved ANDA.
§ 314.97 - Supplements and other changes to an approved ANDA.
§ 314.98 - Postmarketing reports.
§ 314.99 - Other responsibilities of an applicant of an ANDA.
Subpart D - FDA Action on Applications and Abbreviated Applications
§ 314.100 - Timeframes for reviewing applications and abbreviated applications.
§ 314.101 - Filing an NDA and receiving an ANDA.
§ 314.102 - Communications between FDA and applicants.
§ 314.103 - Dispute resolution.
§ 314.104 - Drugs with potential for abuse.
§ 314.105 - Approval of an NDA and an ANDA.
§ 314.106 - Foreign data.
§ 314.107 - Date of approval of a 505(b)(2) application or ANDA.
§ 314.108 - New drug product exclusivity.
§ 314.110 - Complete response letter to the applicant.
§ 314.120 - [Reserved]
§ 314.122 - Submitting an abbreviated application for, or a 505(j)(2)(C) petition that relies on, a listed drug that is no longer marketed.
§ 314.125 - Refusal to approve an NDA.
§ 314.126 - Adequate and well-controlled studies.
§ 314.127 - Refusal to approve an ANDA.
§ 314.150 - Withdrawal of approval of an application or abbreviated application.
§ 314.151 - Withdrawal of approval of an abbreviated new drug application under section 505(j)(5) of the act.
§ 314.152 - Notice of withdrawal of approval of an application or abbreviated application for a new drug.
§ 314.153 - Suspension of approval of an abbreviated new drug application.
§ 314.160 - Approval of an application or abbreviated application for which approval was previously refused, suspended, or withdrawn.
§ 314.161 - Determination of reasons for voluntary withdrawal of a listed drug.
§ 314.162 - Removal of a drug product from the list.
§ 314.170 - Adulteration and misbranding of an approved drug.
Subpart E - Hearing Procedures for New Drugs
§ 314.200 - Notice of opportunity for hearing; notice of participation and request for hearing; grant or denial of hearing.
§ 314.201 - Procedure for hearings.
§ 314.235 - Judicial review.
Subpart F [Reserved]
Subpart G - Miscellaneous Provisions
§ 314.410 - Imports and exports of new drugs.
§ 314.420 - Drug master files.
§ 314.430 - Availability for public disclosure of data and information in an application or abbreviated application.
§ 314.440 - Addresses for applications and abbreviated applications.
§ 314.445 - Guidance documents.
Subpart H - Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses
§ 314.500 - Scope.
§ 314.510 - Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
§ 314.520 - Approval with restrictions to assure safe use.
§ 314.530 - Withdrawal procedures.
§ 314.540 - Postmarketing safety reporting.
§ 314.550 - Promotional materials.
§ 314.560 - Termination of requirements.
Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 355a, 355f, 356, 356a, 356b, 356c, 356e, 360cc, 371, 374, 379e, 379k-1.
Source: 50 FR 7493, Feb. 22, 1985, unless otherwise noted.
This website has been translated to Spanish from English, and is updated often. It is possible that some links will connect you to content only available in English or some of the words on the page will appear in English until translation has been completed (usually within 24 hours). We appreciate your patience with the translation process. In the case of any discrepancy in meaning, the English version is considered official. Thank you for visiting esp.fda.gov/tabaco.
Page Last Updated: 03/22/2024